Antioxidant activity and structural modifications of serum chondroitin sulfate in Graves' disease

Clinical Biochemistry

Volumn 47, Issue 1-2, 2014, Pages 19-24

  Winsz Szczotka, Katarzyna ^a   Komosińska Vassev, Katarzyna ^a   Kuźnik Trocha, Kornelia ^a   Olczyk, Krystyna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Antioxidants; Biomarkers of oxidative stress; Chondroitin sulfate; Graves' disease

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; LIOTHYRONINE; THIAMAZOLE; THIOL GROUP; THYROTROPIN;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROPHORESIS; EXTRACELLULAR MATRIX; GRAVES DISEASE; HUMAN; IMMUNOASSAY; LIOTHYRONINE BLOOD LEVEL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; SULFATION; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL;

ANTIOXIDANTS; BIOMARKERS OF OXIDATIVE STRESS; CHONDROITIN SULFATE; GRAVES' DISEASE;

ANTIOXIDANTS; CHONDROITIN SULFATES; GRAVES DISEASE; HUMANS;

EID: 84890549455     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.08.002     Document Type: Article

References (33)

1. Khalilzadeh O., Noshad S., Rashidi A., Amirzargar A. Graves' ophthalmopathy: a review of immunogenetics. Curr Genomics 2011, 12:564-575.
2. Winsz-Szczotka K., Komosińska-Vassev K., Olczyk K. The metabolism of glycosaminoglycans in the course of Graves' disease. Postepy Hig Med Dosw 2006, 60:184-191.
3. Lehmann G.M., Feldon S.E., Smith T.J., Phipps R.P. Immune mechanisms in thyroid eye disease. Thyroid 2008, 18:959-965.
4. Stan M.N., Bahn R.S. Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid 2010, 20:777-783.
5. Akarsu E., Buyukhatipoglu H., Aktaran S., Kurtul N. Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves' ophthalmopathy. Clin Endocrinol 2011, 74:118-124.
6. Campo G.M., Avenoso A., Campo S., D'Ascola A., Ferlazzo A.M., Samà D., et al. Purified human chondroitin-4-sulfate reduced MMP/TIMP imbalance induced by iron plus ascorbate in human fibroblast cultures. Cell Biol Int 2006, 30:21-30.
7. Gandhi N.S., Mancera R.L. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008, 72:455-482.
8. Handel T.M., Johnson Z., Crown S.E., Lau E.K., Proudfoot A.E. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu Rev Biochem 2005, 74:385-410.
9. Lauder R.M. Chondroitin sulfate: a complex molecule with potential impacts on a wide range of biological systems. Complement Ther Med 2009, 17:56-62.
10. Volpi N., Maccari F. Chondroitin sulfate in normal human plasma is modified depending on the age. Its evaluation in patients with pseudoxanthoma elasticum. Clin Chim Acta 2006, 370:196-200.
11. Volpi N. Anti-inflammatory activity of chondroitin sulfate: new functions from an old natural macromolecule. Inflammopharmacology 2011, 19:299-306.
12. Campo G.M., Avenoso A., D'Ascola A., Campo S., Ferlazzo A.M., Samà D., et al. Purified human plasma glycosaminoglycans limit oxidative injury induced by iron plus ascorbate in skin fibroblast cultures. Toxicol In Vitro 2005, 19:561-572.
13. Maeda N., Ishii M., Nishimura K., Kamimura K. Functions of chondroitin sulfate and heparan sulfate in the developing brain. Neurochem Res 2011, 36:1228-1240.
14. du Souich P., García A.G., Vergés J., Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulfate. J Cell Mol Med 2009, 13:1451-1463.
15. Hansen C., Rouhi R., Förster G., Kahaly G.J. Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. J Clin Endocrinol Metab 1999, 84:1409-1413.
16. Zarković M. The role of oxidative stress on the pathogenesis of Graves' disease. J Thyroid Res 2012, 2012:302537. 10.1155/2012/302537.
17. Bednarek J., Wysocki H., Sowiński J. Oxidative stress peripheral parameters in Graves' disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy. Clin Biochem 2005, 38:13-18.
18. Venditti P., Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 2006, 63:414-434.
19. Tsai C.C., Wu S.B., Cheng C.Y., Kao S.C., Kau H.C., Lee S.M., et al. Increased response to oxidative stress challenge in Graves' ophthalmopathy orbital fibroblasts. Mol Vis 2011, 17:2782-2788.
20. Bartalena L., Tanda M.L., Piantanida E., Lai A. Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 2003, 19:155-163.
21. Egea J., García A.G., Verges J., Montell E., López M.G. Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans. Osteoarthritis Cartilage 2010, 18:24-27.
22. Volpi N., Cusmano M., Venturelli T. Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim Biophys Acta 1995, 18:49-58.
23. Olczyk K., Głowacki A., Koźma E. Non-insulin-dependent diabetes mellitus-associated changes in serum glycosaminoglycans. Pathophysiology 1997, 4:121-129.
24. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal Biochem 1973, 54:484-489.
25. Volpi N. Disaccharide analysis and molecular mass determination to microgram level of single sulfated glycosaminoglycan species in mixtures following agarose-gel electrophoresis. Anal Biochem 1999, 10:229-239.
26. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
27. Hadjigogos K. The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med 2003, 45:7-13.
28. Honke K., Taniguchi N. Sulfotransferases and sulfated oligosaccharides. Med Res Rev 2002, 22:637-654.
29. Klüppel M., Wight T.N., Chan C., Hinek A., Wrana J.L. Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. Development 2005, 132:3989-4003.
30. Campo G.M., Avenoso A., Campo S., D'Ascola A., Traina P., Samà D., et al. Purified human plasma glycosaminoglycans reduced NF-kappaB activation, pro-inflammatory cytokine production and apoptosis in LPS-treated chondrocytes. Innate Immun 2008, 14:233-246.
31. Vallières M., du Souich P. Modulation of inflammation by chondroitin sulfate. Osteoarthritis Cartilage 2010, 18:1-6.
32. Campo G.M., Avenoso A., Campo S., Nastasi G., Traina P., D'Ascola A., et al. The antioxidant activity of chondroitin-4-sulfate, in carbon tetrachloride-induced acute hepatitis in mice, involves NF-kappaB and caspase activation. Br J Pharmacol 2008, 155:945-956.
33. Imai Y., Ibaraki K., Odajima R., Shishiba Y. Analysis of proteoglycan synthesis by retro-ocular tissue fibroblasts under the influence of interleukin 1 beta and transforming growth factor-beta. Eur J Endocrinol 1994, 131:630-638.